Rui Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rui Feng has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Qing Jiang
Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications - Xiaoliang Hua
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
2 shared publications - Chaozhao Liang
Department of Urology the First Affiliated Hospital of Anhui Medical University Hefei China
1 shared publication - Cheng Yang
Key Laboratory of Stem Cell and Biopharmaceutical Technology, Guangxi Normal University, Guilin, 541004, China; School of Life Sciences, Guangxi Normal University, China Guangxi Universities, Guilin, 541004, China; Joint Medical Research Center of Guangxi Normal University & Guilin Hospital of Chinese Traditional and Western Medicine, Guangxi Normal University, Guilin, 541004, China
1 shared publication - Cheng Yang
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China
1 shared publication - Chunyan Chen
Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
1 shared publication
Latest Publications
- 5 March 2024
- Published by Wiley in The Prostate
- Vol. 84 (7) , 666-681
Sodium butyrate alleviates experimental autoimmune prostatitis by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO‐1 pathway
Background: Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) leads to severe discomfort in males and loss of sperm quality. Current therapeutic options have failed to achieve satisfactory results. Sodium butyrate (NaB) plays a beneficial role in reducing inflammation, increasing antioxidant capacities, and improving organ dysfunction; additionally NaB has good safety prospects and great potential for clinical application. The purpose of the current research was to study the effect of NaB on CP/CPPS and the underlying mechanisms using a mouse model of experimental autoimmune prostatitis (EAP) mice.Methods: The EAP mouse model was successfully established by subcutaneously injecting a mixture of prostate antigen and complete Freund's adjuvant. Then, EAP mice received daily intraperitoneal injections of NaB (100, 200, or 400 mg/kg/day) for 16 days, from Days 26 to 42. We then explored anti‐inflammatory potential mechanisms of NaB by studying the effects of Nrf2 inhibitor ML385 and HO‐1 inhibitor zinc protoporphyrin on prostate inflammation and pelvic pain using this model. On Day 42, hematoxylin‐eosin staining and dihydroethidium staining were used to evaluate the histological changes and oxidative stress levels of prostate tissues. Chronic pelvic pain was assessed by applying Von Frey filaments to the lower abdomen. The levels of inflammation‐related cytokines, such as interleukin (IL)−1β, IL‐6, and tumor necrosis factor were detected by enzyme‐linked immunosorbent assay. The regulation of Nrf2/HO‐1 signaling pathway and the expression of NLRP3 inflammasome‐related protein in EAP mice were detected by western blot analysis assay.Results: Compared with the EAP group, chronic pain development, histological manifestations, and cytokine levels showed that NaB reduced the severity of EAP. NaB treatment could inhibit NLRP3 inflammasome activation. Mechanism studies showed that NaB intervention could alleviate oxidative stress in EAP mice through Nrf2/HO‐1 signal pathway. Nrf2/HO‐1 pathway inhibitors can inhibit NaB ‐mediated oxidative stress. The inhibitory effect of NaB on the activation of NLRP3 inflammasome and anti‐inflammatory effect can also be blocked by Nrf2/HO‐1 pathway.Conclusions: NaB treatment can alleviates prostatic inflammation and pelvic pain associated with EAP by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO‐1 pathway. NaB has the potential as an effective agent in the treatment of EAP.
- 5 March 2024
- Published by Wiley in The Prostate
- Vol. 84 (7) , 666-681
Sodium butyrate alleviates experimental autoimmune prostatitis by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO‐1 pathway
Background: Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) leads to severe discomfort in males and loss of sperm quality. Current therapeutic options have failed to achieve satisfactory results. Sodium butyrate (NaB) plays a beneficial role in reducing inflammation, increasing antioxidant capacities, and improving organ dysfunction; additionally NaB has good safety prospects and great potential for clinical application. The purpose of the current research was to study the effect of NaB on CP/CPPS and the underlying mechanisms using a mouse model of experimental autoimmune prostatitis (EAP) mice.Methods: The EAP mouse model was successfully established by subcutaneously injecting a mixture of prostate antigen and complete Freund's adjuvant. Then, EAP mice received daily intraperitoneal injections of NaB (100, 200, or 400 mg/kg/day) for 16 days, from Days 26 to 42. We then explored anti‐inflammatory potential mechanisms of NaB by studying the effects of Nrf2 inhibitor ML385 and HO‐1 inhibitor zinc protoporphyrin on prostate inflammation and pelvic pain using this model. On Day 42, hematoxylin‐eosin staining and dihydroethidium staining were used to evaluate the histological changes and oxidative stress levels of prostate tissues. Chronic pelvic pain was assessed by applying Von Frey filaments to the lower abdomen. The levels of inflammation‐related cytokines, such as interleukin (IL)−1β, IL‐6, and tumor necrosis factor were detected by enzyme‐linked immunosorbent assay. The regulation of Nrf2/HO‐1 signaling pathway and the expression of NLRP3 inflammasome‐related protein in EAP mice were detected by western blot analysis assay.Results: Compared with the EAP group, chronic pain development, histological manifestations, and cytokine levels showed that NaB reduced the severity of EAP. NaB treatment could inhibit NLRP3 inflammasome activation. Mechanism studies showed that NaB intervention could alleviate oxidative stress in EAP mice through Nrf2/HO‐1 signal pathway. Nrf2/HO‐1 pathway inhibitors can inhibit NaB ‐mediated oxidative stress. The inhibitory effect of NaB on the activation of NLRP3 inflammasome and anti‐inflammatory effect can also be blocked by Nrf2/HO‐1 pathway.Conclusions: NaB treatment can alleviates prostatic inflammation and pelvic pain associated with EAP by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO‐1 pathway. NaB has the potential as an effective agent in the treatment of EAP.
- Open Access
- 1 August 2023
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 16, 3365-3379
Resolvin D1 Attenuates Inflammation and Pelvic Pain Associated with EAP by Inhibiting Oxidative Stress and NLRP3 Inflammasome Activation via the Nrf2/HO-1 Pathway
Background: Resolvin D1 (RvD1), a member of the specialized pro-resolving lipid mediators family, has a potent anti-inflammatory effect and alleviates tissue damage. The purpose of the current research was to study the effect of RvD1 on CP/CPPS and the underlying mechanisms using a mouse model of experimental autoimmune prostatitis (EAP) mice. Materials and Methods: The EAP mouse model was successfully established, and was used to test the therapeutic effect of RvD1. Hematoxylin-eosin staining and dihydroethidium staining were used to evaluate the histological changes and oxidative stress levels of prostate tissues. Chronic pelvic pain was assessed by applying von Frey filaments to the lower abdomen. The superoxide dismutase enzyme and malondialdehyde levels were detected using enzyme-linked immunosorbent assay (ELISA). The levels of inflammation-related cytokines, including IL-1β, IL-6, and TNF-α were detected by ELISA. Results: RvD1 treatment ameliorated prostatic inflammation and the pelvic pain of EAP mice. RvD1 treatment could inhibit activation of the NLRP3 inflammasome and oxidative stress. RvD1 treatment could activate Nrf2/HO-1 signaling in mice with EAP. Blockade of Nrf2/HO-1 signaling abolished the RvD1-mediated inhibition of oxidative stress, NLRP3 inflammasome activation and the anti-inflammatory effect of RvD1 in EAP. Conclusion: RvD1 treatment can reduce inflammatory cell infiltration in prostate tissue and attenuate pelvic pain associated with EAP by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO-1 pathway. These results provide new insights that RvD1 has the potential as an effective agent in the treatment of EAP.
- 1 August 2023
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 16, 3365-3379
Open AccessResolvin D1 Attenuates Inflammation and Pelvic Pain Associated with EAP by Inhibiting Oxidative Stress and NLRP3 Inflammasome Activation via the Nrf2/HO-1 Pathway
Background: Resolvin D1 (RvD1), a member of the specialized pro-resolving lipid mediators family, has a potent anti-inflammatory effect and alleviates tissue damage. The purpose of the current research was to study the effect of RvD1 on CP/CPPS and the underlying mechanisms using a mouse model of experimental autoimmune prostatitis (EAP) mice. Materials and Methods: The EAP mouse model was successfully established, and was used to test the therapeutic effect of RvD1. Hematoxylin-eosin staining and dihydroethidium staining were used to evaluate the histological changes and oxidative stress levels of prostate tissues. Chronic pelvic pain was assessed by applying von Frey filaments to the lower abdomen. The superoxide dismutase enzyme and malondialdehyde levels were detected using enzyme-linked immunosorbent assay (ELISA). The levels of inflammation-related cytokines, including IL-1β, IL-6, and TNF-α were detected by ELISA. Results: RvD1 treatment ameliorated prostatic inflammation and the pelvic pain of EAP mice. RvD1 treatment could inhibit activation of the NLRP3 inflammasome and oxidative stress. RvD1 treatment could activate Nrf2/HO-1 signaling in mice with EAP. Blockade of Nrf2/HO-1 signaling abolished the RvD1-mediated inhibition of oxidative stress, NLRP3 inflammasome activation and the anti-inflammatory effect of RvD1 in EAP. Conclusion: RvD1 treatment can reduce inflammatory cell infiltration in prostate tissue and attenuate pelvic pain associated with EAP by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO-1 pathway. These results provide new insights that RvD1 has the potential as an effective agent in the treatment of EAP.
- 23 May 2017
- Published by Wiley in British Journal of Haematology
- Vol. 182 (2) , 305-307
GPIIb/IIIa autoantibody predicts better rituximab response in ITP
- 23 May 2017
- Published by Wiley in British Journal of Haematology
- Vol. 182 (2) , 305-307
GPIIb/IIIa autoantibody predicts better rituximab response in ITP